t.tulloch

TL2 Moderator · Antalya

Contributes reviews on supplier material. Based in Antalya.

Joined 12 April 2025 · last posted 6h

90Posts here

2Topics

0Solutions

1.9kLikes received

819Likes given

23Badges

255Days visited

5.4kPosts read

Recent activity

Full stream

eGFR fluctuation and the creatinine denominator problem — the long version Replied, post #47 · Clinical › Bloodwork · 28 Jul 2026 · 3 likes Biological variation: the person-to-person variation in a biomarker for a healthy person is larger than most people realize. Comparing your result to the reference…
Trust level 3 requirements: a clarification — does this still hold? Replied, post #86 · Meta › Announcements · 20 Jul 2026 · 19 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
Tracking a shortage from primary sources rather than rumour Replied, post #97 · Access › Shortages · 11 Jul 2026 · 29 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
[2026 update] Antibiotics and a course of something with delayed emptying Replied, post #20 · Practice › Interactions · 7 Jul 2026 · 0 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #23 · Evidence › Journal club · 4 Jul 2026 · 24 likes Picking up post #20: that is the part I would want checked first. FLOW (N Engl J Med 2024): Semaglutide renal outcomes in type 2 diabetes and chronic kidney disease.…
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #53 · Compounds › Repair & healing peptides · 4 Jul 2026 · 7 likes Worth separating two things that post #49 runs together. For anyone arriving from search engines: this subcategory discusses published preclinical work and the absence…
Prescription portability between countries Replied, post #80 · Access › International · 28 Jun 2026 · 4 likes On post #76 — agreed on the reasoning, with one qualification. Insurance and coverage: coverage decisions are national. A compound approved in one country might not be…
Ultrasound and skinfolds: operator dependence in practice Replied, post #34 · Outcomes › Body composition · 28 Jun 2026 · 0 likes Comparison to published data: the trials reported mean fat and lean mass changes. Individual results vary around that mean. Being above or below average is not a sign…
Personal or family history of medullary thyroid carcinoma — what changed since Replied, post #86 · Safety › Contraindications · 25 Jun 2026 · 18 likes Worth separating two things that post #82 runs together. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather…
Reading a trial's population section before its results Replied, post #98 · Evidence › Trials · 7 Jun 2026 · 26 likes Population narrowness: most trials in this class enrolled fairly specific groups. Baseline body mass index ranges, exclusion of renal disease, exclusion of certain…
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #35 · Evidence › Journal club · 5 Jun 2026 · 15 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
Peak-to-trough ratio at steady state for a weekly agent Replied, post #19 · Pharmacology › Pharmacokinetics · 31 May 2026 · 21 likes Half-life: semaglutide ≈ 165–184 hours (about a week). Tirzepatide ≈ 5 days. Liraglutide ≈ 13 hours. The half-life determines how much accumulation happens at steady…